Assenagon Asset Management S.A. Acquires 22,555 Shares of United Therapeutics Corporation $UTHR

Assenagon Asset Management S.A. raised its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 91.6% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 47,183 shares of the biotechnology company’s stock after purchasing an additional 22,555 shares during the period. Assenagon Asset Management S.A.’s holdings in United Therapeutics were worth $27,979,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of the company. Torren Management LLC purchased a new position in shares of United Therapeutics in the 4th quarter valued at approximately $26,000. Activest Wealth Management boosted its stake in shares of United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after buying an additional 56 shares during the last quarter. Entrust Financial LLC purchased a new stake in United Therapeutics in the 4th quarter worth approximately $31,000. Wilmington Savings Fund Society FSB grew its stake in shares of United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares during the period. Finally, Harbor Capital Advisors Inc. purchased a new position in shares of United Therapeutics during the 4th quarter valued at approximately $48,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $542.66 on Friday. The stock has a market capitalization of $23.04 billion, a P/E ratio of 20.03, a price-to-earnings-growth ratio of 1.79 and a beta of 0.57. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $609.35. The company has a 50 day moving average price of $561.23 and a 200 day moving average price of $525.58.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. During the same quarter in the prior year, the firm earned $6.63 EPS. The firm’s revenue was down 1.6% compared to the same quarter last year. On average, research analysts forecast that United Therapeutics Corporation will post 26.49 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

UTHR has been the subject of several analyst reports. Cantor Fitzgerald boosted their target price on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. Morgan Stanley set a $516.00 price objective on shares of United Therapeutics in a report on Thursday, May 7th. Bank of America boosted their target price on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 31st. Raymond James Financial initiated coverage on United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 price target on the stock. Finally, TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $619.42.

Insider Buying and Selling

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction on Monday, April 6th. The shares were sold at an average price of $558.40, for a total transaction of $5,584,000.00. Following the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at approximately $10,540,358.40. This trade represents a 34.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 643,218 shares of company stock worth $363,705,304 over the last quarter. Insiders own 8.60% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.